87 related articles for article (PubMed ID: 16211462)
1. Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer.
Dent SF; Arnold A; Stewart DJ; Gertler S; Ayoub J; Batist G; Goss G; Nevile A; Soulieres D; Jolivet J; McLntosh L; Seymour L
Lung; 2005; 183(4):265-72. PubMed ID: 16211462
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
[TBL] [Abstract][Full Text] [Related]
3. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
de Bono JS; Stephenson J; Baker SD; Hidalgo M; Patnaik A; Hammond LA; Weiss G; Goetz A; Siu L; Simmons C; Jolivet J; Rowinsky EK
J Clin Oncol; 2002 Jan; 20(1):96-109. PubMed ID: 11773159
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Giles FJ; Garcia-Manero G; Cortes JE; Baker SD; Miller CB; O'Brien SM; Thomas DA; Andreeff M; Bivins C; Jolivet J; Kantarjian HM
J Clin Oncol; 2002 Feb; 20(3):656-64. PubMed ID: 11821445
[TBL] [Abstract][Full Text] [Related]
5. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Giles FJ; Cortes JE; Baker SD; Thomas DA; O'Brien S; Smith TL; Beran M; Bivins C; Jolivet J; Kantarjian HM
J Clin Oncol; 2001 Feb; 19(3):762-71. PubMed ID: 11157029
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors.
Lapointe R; Létourneau R; Steward W; Hawkins RE; Batist G; Vincent M; Whittom R; Eatock M; Jolivet J; Moore M
Ann Oncol; 2005 Feb; 16(2):289-93. PubMed ID: 15668286
[TBL] [Abstract][Full Text] [Related]
7. Troxacitabine: BCH 4556, SPD 758, Troxatyl.
Adis International Ltd
Drugs R D; 2003; 4(4):264-8. PubMed ID: 12848594
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
Bélanger K; Moore M; Baker SD; Dionne J; Maclean M; Jolivet J; Siu L; Soulières D; Wainman N; Seymour L
J Clin Oncol; 2002 May; 20(10):2567-74. PubMed ID: 12011137
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Giles FJ; Feldman EJ; Roboz GJ; Larson RA; Mamus SW; Cortes JE; Verstovsek S; Faderl S; Talpaz M; Beran M; Albitar M; O'Brien SM; Kantarjian HM
Leuk Res; 2003 Dec; 27(12):1091-6. PubMed ID: 12921945
[TBL] [Abstract][Full Text] [Related]
10. A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
Vose JM; Panwalkar A; Belanger R; Coiffier B; Baccarani M; Gregory SA; Facon T; Fanin R; Caballero D; Ben-Yehuda D; Giles F
Leuk Lymphoma; 2007 Jan; 48(1):39-45. PubMed ID: 17325846
[TBL] [Abstract][Full Text] [Related]
11. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Eisenhauer E; Butts C; Gregg R; Dancey J; Fisher B; Iglesias J
J Clin Oncol; 1999 Apr; 17(4):1194. PubMed ID: 10561178
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Lin CC; Beeram M; Rowinsky EK; Takimoto CH; Ng CM; Geyer CE; Denis LJ; De Bono JS; Hao D; Tolcher AW; Rha SY; Jolivet J; Patnaik A
Cancer Chemother Pharmacol; 2009 Dec; 65(1):167-75. PubMed ID: 19449006
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Roboz GJ; Giles FJ; Ritchie EK; Allen-Bard S; Curcio TJ; Wilkes MA; Park SL; Kantarjian HM; Faderl S; Ravandi F; Kelner MJ; Feldman EJ
J Clin Oncol; 2007 Jan; 25(1):10-5. PubMed ID: 17146106
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
Perez-Soler R; Fossella FV; Glisson BS; Lee JS; Murphy WK; Shin DM; Kemp BL; Lee JJ; Kane J; Robinson RA; Lippman SM; Kurie JM; Huber MH; Raber MN; Hong WK
J Clin Oncol; 1996 Feb; 14(2):503-13. PubMed ID: 8636764
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of oral topotecan in advanced non-small cell lung cancer.
White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
Jimeno A; Messersmith WA; Lee CK; Ma WW; Laheru D; Donehower RC; Baker SD; Hidalgo M
Ann Oncol; 2008 Feb; 19(2):374-9. PubMed ID: 18245131
[TBL] [Abstract][Full Text] [Related]
17. [Troxacitabine].
Gourdeau H; Jolivet J
Bull Cancer; 2004 Mar; 91(3):213-8. PubMed ID: 15171046
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
Johnson DH; Paul DM; Hande KR; DeVore R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
[TBL] [Abstract][Full Text] [Related]
19. Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
Lam W; Bussom S; Cheng YC
Mol Cancer Ther; 2009 Feb; 8(2):415-23. PubMed ID: 19208827
[TBL] [Abstract][Full Text] [Related]
20. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]